Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
oncolytic virus therapy |
| gptkbp:administeredBy |
intratumoral injection
|
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L03AX21
|
| gptkbp:brand |
Imlygic
|
| gptkbp:contraindication |
immunocompromised patients
|
| gptkbp:derivedFrom |
gptkb:herpes_simplex_virus_type_1
|
| gptkbp:developer |
gptkb:Amgen
|
| gptkbp:form |
solution for injection
|
| https://www.w3.org/2000/01/rdf-schema#label |
Talimogene laherparepvec
|
| gptkbp:indication |
unresectable cutaneous, subcutaneous, and nodal lesions in melanoma
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
expression of GM-CSF
selective replication in tumor cells |
| gptkbp:routeOfAdministration |
intralesional
|
| gptkbp:sideEffect |
nausea
fatigue chills pyrexia flu-like symptoms |
| gptkbp:storage |
frozen
|
| gptkbp:target |
tumor cells
|
| gptkbp:usedFor |
melanoma
|
| gptkbp:bfsParent |
gptkb:L03AX13
|
| gptkbp:bfsLayer |
7
|